GlaxoSmithKline

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Public

Established: 1929-01-01

Employees: 70.2K

Market Cap: $90B

Website: http://www.gsk.com

Introduction: GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Clinical Trials

Safety of Inhaled Zanamivir in Pregnancy

Completed

Conditions: Influenza, Human

Interventions: Drug: Treatment with zanamivir

First Posted Date: 2011-10-31

Last Posted Date: 2014-04-21

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 1

Registration Number: NCT01462487

Physician Liver Function Test (LFT) Monitoring for Tykerb Pts

Completed

Conditions: Cancer

Interventions: Drug: Lapatanib

First Posted Date: 2011-10-31

Last Posted Date: 2015-04-15

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 1

Registration Number: NCT01462552

Pilot Study of Patient's Adherence to TYKERB™/TYVERB™ + Capecitabine in Metastatic Breast Cancer

Completed

Conditions: Cancer

Interventions: Other: non-drug intervention educational programme

First Posted Date: 2011-10-31

Last Posted Date: 2018-06-19

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 27

Registration Number: NCT01462604

Locations: 🇸🇬
GSK Investigational Site, Singapore, Singapore

Risk of Urinary Retention With Retigabine

Terminated

Conditions: Epilepsy

Interventions: Drug: Non-EZG containing AED polytherapy
Drug: EZG containing AED polytherapy
Drug: Non-EZG AED monotherapy
Drug: EZG AED monotherapy

First Posted Date: 2011-10-31

Last Posted Date: 2016-11-25

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 1

Registration Number: NCT01462656

Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' Human Papillomavirus (HPV) Vaccine (GSK-580299) and Merck's Gardasil Vaccine When Administered According to Alternative 2-dose Schedules in 9-14 Year Old Females

Phase 3

Completed

Conditions: Infections, Papillomavirus

Interventions: Biological: Gardasil
Biological: Cervarix
Drug: Placebo

First Posted Date: 2011-10-31

Last Posted Date: 2019-11-15

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 1079

Registration Number: NCT01462357

Locations: 🇸🇪
GSK Investigational Site, Örebro, Sweden

6-month Safety and Benefit Study of ADVAIR in Children 4-11 Years Old

Phase 4

Completed

Conditions: Asthma

Interventions: Drug: ADVAIR 250/50mcg
Drug: ADVAIR 100/50mcg
Drug: FLOVENT 250mcg
Drug: FLOVENT 100mcg

First Posted Date: 2011-10-31

Last Posted Date: 2018-08-06

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 6250

Registration Number: NCT01462344

Locations: 🇬🇧
GSK Investigational Site, Surrey, United Kingdom

A Clinical Study to Assess Two Doses of GSK2402968 in Subjects With Duchenne Muscular Dystrophy (DMD)

Phase 2

Completed

Conditions: Muscular Dystrophies

Interventions: Drug: Placebo to match GSK2402968 6 mg/kg/week
Drug: GSK2402968 3mg/kg/week
Drug: GSK2402968 6 mg/kg/week
Drug: Placebo to match GSK2402968 3 mg/kg/week